News

VANCOUVER, BRITISH COLUMBIA, September 11, 2017 - Pascal Biosciences Inc. (TSX.V:PAS) (“Pascal” or the “Company”), a drug discovery and development company, today announced that the Company has executed an exclusive, worldwide license option agreement with STC.UNM (“STC”), the University of New…

VANCOUVER, BRITISH COLUMBIA, May 9, 2017 --Pascal Biosciences Inc. (formerly bioMmune Technologies Inc.) (TSX.V/PAS) (“Pascal” or the “Company”), a biotechnology company that specializes in drug discovery and development, is pleased to announce that the Company has created a new, wholly…

VANCOUVER, BRITISH COLUMBIA, March 30, 2017 -- bioMmune Technologies Inc. (TSX.V: IMU) (the “Company”), a Vancouver-based biotechnology company, is pleased to announce that effective Thursday, March 30, 2017, the Company has changed its name to Pascal Biosciences Inc. (“Pascal”). Effective…

VANCOUVER, BRITISH COLUMBIA, November 14, 2016 -- bioMmune Technologies Inc. (TSX.V: IMU) (the “Company”) announces the approval and adoption by its Board of Directors of an advance notice policy (the "Policy"). The purpose of the Policy is to provide shareholders,…

VANCOUVER, BRITISH COLUMBIA, October 5, 2016 -- bioMmune Technologies Inc. (TSX.V: IMU) (the “Company”) is pleased to announce that pursuant to the Company’s Incentive Stock Option Plan (the “Plan”), it has granted incentive stock options to directors and officers of the Company…

Vancouver, British Columbia, September 20, 2016 -– bioMmune Technologies Inc. (“bioMmune” or the “Company”) (TSX.V: IMU), a drug discovery and development biotechnology company, today announced the appointment of Dr. Thomas R. Gadek to its Board of Directors. “Tom’s demonstrated success…